基于多种免疫细胞的细胞免疫治疗联合含硼替佐米的化疗方案治疗多发性骨髓瘤的临床观察

发布时间：2019-02-16 01:57

【摘要】：目的:观察分析基于多种免疫细胞的细胞免疫疗法联合含硼替佐米的化疗方案治疗多发性骨髓瘤患者的临床效果。方法:选取2012年10月-2013年10月在我院住院治疗的76例多发性骨髓瘤患者,随机将他们分为2组,1组(38例)采用细胞免疫疗法联合含硼替佐米化疗方案(复合治疗组),另1组(38例)采用含硼替佐米的单纯化疗方案(单纯化疗组),比较2组患者治疗缓解率、免疫表型表达水平变化、无进展生存期(PFS)及不良反应发生情况。结果:复合化疗组总缓解率明显高于单纯化疗组(P0.05);治疗后复合治疗组患者CD38~+、CD56~+、CD138~+和MRD~+表达率均明显低于单纯化疗组,CD19~+表达率均明显高于单纯化疗组(P0.05);复合治疗组1、2、3年PFS均明显长于单纯化疗组(P0.05);复合治疗组乏力、皮疹、周围神经病变、贫血、粒细胞缺乏等方面不良反应发生率均明显低于单纯化疗组(P0.05)。结论:细胞免疫治疗联合含硼替佐米的化疗方案可显著增加多发性骨髓瘤患者的临床治疗疗效,明显提高缓解率的同时显著延长这类患者的生存期,而且可降低部分患者的不良反应的发生率,增加患者的化疗耐受。
[Abstract]:Aim: to observe and analyze the clinical effect of cellular immunotherapy based on multiple immune cells combined with bortezomib chemotherapy in patients with multiple myeloma. Methods: 76 patients with multiple myeloma who were hospitalized in our hospital from October 2012 to October 2013 were randomly divided into two groups: one group (38 cases) was treated with cellular immunotherapy combined with boron tezomil chemotherapy regimen (compound group). Another group (38 cases) was treated with bortezomil alone (chemotherapy group). The remission rate, immunophenotypic expression, progression free survival (PFS) and adverse reaction (ADR) were compared between the two groups. Results: the total remission rate of the combined chemotherapy group was significantly higher than that of the simple chemotherapy group (P0.05). After treatment, the expression rates of CD38~, CD56~, CD138~ and MRD~ in the combined treatment group were significantly lower than those in the chemotherapy alone group, and the CD19~ expression rate was significantly higher in the combined treatment group than in the chemotherapy group (P0.05), the PFS in the combined treatment group was significantly longer than that in the chemotherapy group for 1 and 3 years (P0.05). The incidence of adverse reactions such as fatigue, rash, peripheral neuropathy, anemia and granulocytosis in the combined treatment group was significantly lower than that in the chemotherapy alone group (P0.05). Conclusion: Cellular immunotherapy combined with bortezomil chemotherapy can significantly increase the clinical efficacy of patients with multiple myeloma and significantly increase the remission rate and prolong the survival time of these patients. And can reduce the incidence of adverse reactions in some patients, increase the patient's chemotherapy tolerance.
【作者单位】：重庆市肿瘤研究所/医院/癌症中心、肿瘤内科;
【分类号】：R733.3

【参考文献】